James Bylund - Mar 3, 2025 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role: Chief Operating Officer
Signature: /s/ Marc Baumgartner (Attorney in Fact)
Stock symbol: RGEN
Transactions as of: Mar 3, 2025
Transactions value $: -$192,516
Form type: 4
Date filed: 3/4/2025, 01:29 PM
Previous filing: Feb 28, 2025
Next filing: Mar 20, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RGEN	Common Stock	Award	$0	+6.44K	+34.3%	$0.00	25.2K	Mar 3, 2025	Direct	F1
transaction	RGEN	Common Stock	Tax liability	-$193K	-1.24K	-4.92%	$155.38	24K	Mar 3, 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RGEN	Stock Option (Right to Buy)	Award	$0	+6.06K		$0.00	6.06K	Mar 3, 2025	Common Stock	6.06K	$155.38	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Mr. Bylund was awarded 6,435 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2	Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
F3	One third of the stock options will vest and become exercisable annually on March 3, 2026, March 3, 2027, and March 3, 2028.